MAT Q2 2015 update: Three key dynamic market shifts

Global OTC growth hit 5.7% in MAT June 2015 to total US$124bn, and our accompanying OTC Market Stats update revealed several major changes in the leaderboard. Find out how to delve deeper with the latest edition of OTC DASHBOARD’s user tutorial series, below. Meanwhile, our data team is currently beavering away on the upcoming MAT Q3 2015 update, which we expect to publish online next month – Regards, Owen Hartnett.

1. Perrigo is now a Top 20 OTC company

After purchasing European dynamo Omega Pharma earlier this year, Perrigo has entered the global Top 20 at the expense of Genomma. With this enhanced OTC focus, especially within Europe, Perrigo’s sales reached US$678mn in the reporting period (not including private label OTCs), and CEO Joe Papa believes the company is now better-placed to “capitalise on the many megatrends which bend in favour of consumer choice and cost control in healthcare”.

Meanwhile, Mylan’s proposed acquisition of Perrigo is gathering momentum, with the Federal Trade Commission this month providing the final regulatory clearance needed to close the deal. Perrigo continues to “strongly recommend that its shareholders not tender into Mylan’s inadequate offer”.

Quick tip: Click on any marketer in the Company Watch table to launch a pop-up containing a summary of performance with sales split by major OTC category. 

2. J&J is now the leading US OTC marketer

J&J overtook Bayer to reclaim the No.1 US OTC marketer spot in MAT Q2 2015. This was a result of double-digit growth for its US systemic analgesics portfolio, driven by Tylenol and Motrin in both the adult and paediatric segments. These key brands were recently expanded with Tylenol 8HR Arthritis and Motrin Liquid Gels respectively, as the marketer looks to use innovation as a basis to protect its leading position and fend off increasing competition from private labels.

OTC was also a key driving force in J&J’s latest financial results for Q3 2015, with this unit (as part of its Consumer division) posting a 6.3% upturn thanks to a strong performance in Emerging Markets, particularly Russia.

Screen Shot 2015-11-09 at 10.35.53

Quick tip: Our company results tracking feature offers a provisional look at OTC performance ahead of each quarterly update. See the Charts & Graphs archive for a visual round-up of the leading global players.

3. India is now the No.10 OTC market globally

OTC sales in India grew by 9.8% in MAT Q2 2015, enabling it to leapfrog Canada and enter the global Top 10. The market continues to recover from the price caps introduced under the Drug Price Control Order 2013. Meanwhile, key domestic players such as Dabur are focusing on the urban pharmacy channel to obtain recommendations from pharmacists and expand product availability.

Screen Shot 2015-11-09 at 10.44.40

Quick tip: The Market Overview page for all 62 countries provides a snapshot of economic performance, along with soft information to supplement our sales data.

OTC DASHBOARD is a subscription-only web service powered by Nicholas Hall’s DB6 Global OTC Database. To find out how we can help you to save time, work smarter and keep connected, get in touch with us today at: otcdashboard@NicholasHall.com

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s